Tags

Type your tag names separated by a space and hit enter

Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study.
J Periodontal Res 2002; 37(2):93-100JP

Abstract

The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05, 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (+/- SD) 1.0 +/- 0.5, 3.5 +/- 1.4 and 2.3 +/- 0.4 mm2 for the 0.05, 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 +/- 4%, 18 +/- 10% and 21 +/- 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval.

Authors+Show Affiliations

Section of Periodontology, College of Dentistry, The Ohio State University, Columbus 43218-2351, USA.

Pub Type(s)

Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

12009189

Citation

Tatakis, Dimitris N., et al. "Peri-implant Bone Regeneration Using Recombinant Human Bone Morphogenetic Protein-2 in a Canine Model: a Dose-response Study." Journal of Periodontal Research, vol. 37, no. 2, 2002, pp. 93-100.
Tatakis DN, Koh A, Jin L, et al. Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study. J Periodont Res. 2002;37(2):93-100.
Tatakis, D. N., Koh, A., Jin, L., Wozney, J. M., Rohrer, M. D., & Wikesjö, U. M. (2002). Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study. Journal of Periodontal Research, 37(2), pp. 93-100.
Tatakis DN, et al. Peri-implant Bone Regeneration Using Recombinant Human Bone Morphogenetic Protein-2 in a Canine Model: a Dose-response Study. J Periodont Res. 2002;37(2):93-100. PubMed PMID: 12009189.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Peri-implant bone regeneration using recombinant human bone morphogenetic protein-2 in a canine model: a dose-response study. AU - Tatakis,Dimitris N, AU - Koh,Alexander, AU - Jin,Lisa, AU - Wozney,John M, AU - Rohrer,Michael D, AU - Wikesjö,Ulf M E, PY - 2002/5/15/pubmed PY - 2002/8/3/medline PY - 2002/5/15/entrez SP - 93 EP - 100 JF - Journal of periodontal research JO - J. Periodont. Res. VL - 37 IS - 2 N2 - The objective of this study was to evaluate the effect of recombinant human bone morphogenetic protein-2 (rhBMP-2) dose on alveolar ridge augmentation and dental implant osseointegration. Bilateral, 5 mm supraalveolar, peri-implant defects were surgically created in 6 beagle dogs. rhBMP-2 (0.05, 0.1 or 0.2 mg/ml) in an absorbable collagen sponge (ACS) carrier was molded around the fixtures and wounds were closed. Treatment variations were alternated between animals (incomplete block design). Animals were sacrificed at week 8 postsurgery. Nine of twelve jaw quadrants healed uneventfully. Two jaw quadrants exhibited wound failure by week 4 and one by week 8 postsurgery. Radiographic bone regeneration was observed in defects without wound failure from week 4 postsurgery. Radiolucent voids of variable size and shape were observed and regressed over time. In weeks 6 through 8, there was an apparent increase in bone density and trabecular structure, while bone height and volume decreased. Histometric analysis revealed limited differences in bone regeneration between experimental conditions. Bone regeneration area averaged (+/- SD) 1.0 +/- 0.5, 3.5 +/- 1.4 and 2.3 +/- 0.4 mm2 for the 0.05, 0.1 and 0.2 mg/ml dose, respectively. There were no significant differences in osseointegration. Osseointegration in newly formed bone averaged 19 +/- 4%, 18 +/- 10% and 21 +/- 6% for the 0.05, 0.1 and 0.2 mg/ml rhBMP-2 sites, respectively. Collectively, the data suggest that there are no dramatic differences in bone induction and osseointegration within the selected dose and observation interval. SN - 0022-3484 UR - https://www.unboundmedicine.com/medline/citation/12009189/Peri_implant_bone_regeneration_using_recombinant_human_bone_morphogenetic_protein_2_in_a_canine_model:_a_dose_response_study_ L2 - https://onlinelibrary.wiley.com/resolve/openurl?genre=article&sid=nlm:pubmed&issn=0022-3484&date=2002&volume=37&issue=2&spage=93 DB - PRIME DP - Unbound Medicine ER -